Showing 1181-1190 of 1308 results for "".
- Iveric Bio Submits First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophyhttps://modernod.com/news/iveric-bio-submits-first-part-of-nda-for-rolling-review-of-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy/2481227/Iveric bio announced that it has submitted to the FDA the first part of its new drug application (NDA) for rolling review of avacincaptad pegol (ACP, also known as Zimura) a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to age-related m
- Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-submits-new-drug-application-to-the-fda-for-tp-03-for-the-treatment-of-demodex-blepharitis/2481073/Tarsus Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis. Demodex blepharitis is a highly prevalent eyelid m
- Glaukos Announces More Than 1 Million iStent Devices Implanted Worldwidehttps://modernod.com/news/glaukos-announces-more-than-1-million-istent-devices-implanted-worldwide/2481064/Glaukos announced that it has reached a milestone with its iStent family of technologies having now been implanted in more than 1 million procedures worldwide. “One million iStents implanted is a tremendous accomplishment and I’m grate
- Ocuphire Extends US Patent Protection for Drug Candidate Nyxol for Reversal of Mydriasis by 5 More Years Into 2039https://modernod.com/news/ocuphire-extends-us-patent-protection-for-drug-candidate-nyxol-for-reversal-of-mydriasis-by-5-more-years-into-2039/2481011/Ocuphire Pharma announced the issuance of a new U.S. Patent (No. 11,400,077), which provides added intellectual property protection for the company’s late-stage product candidate, Nyxol (phentolamine mesylate), with claims directed to methods for treating mydriasis using phentolamine m
- Global Data: Increasing Cataract Surgical Rates Will Drive Artificial Lenses Market to Reach $4.7 Billion by 2030https://modernod.com/news/global-data-increasing-cataract-surgical-rates-will-drive-artificial-lenses-market-to-reach-47-billion-by-2030/2480953/The global market for IOLs is forecast by GlobalData to steadily grow from $4.3 billion in 2021 to $4.7 billion by the end of the decade. The data and analytics company notes that this growth is primarily driven by the growing capacity of many hospitals and clinics across all regions to perform m
- EssilorLuxottica Chairman Leonardo Del Vecchio Passes Away at Age 87https://modernod.com/news/essilorluxottica-chairman-leonardo-del-vecchio-passes-away-at-age-87/2480931/Italian fashion icon Leonardo Del Vecchio, chairman of EssilorLuxottica, passed away at the age of 87, the company announced Monday. "The company expresses its deepest condolences to the family and to the global employee community for this enormous loss. The Board will m
- Alcon Announces Scientific Program at ASCRS 2022https://modernod.com/news/alcon-announces-scientific-program-at-ascrs-2022/2480782/Alcon will once again have a significant scientific presence at the American Society of Cataract and Refractive Surgery (ASCRS) 2022 annual meeting, taking place April 22-26 in Washington, DC. Approximately 150 abstracts feature Alcon’s leading ophthalmic products and equipment—with m
- Bausch Health Files for Solta IPOhttps://modernod.com/news/bausch-health-files-for-solta-ipo/2480629/Bausch Health Companies announced today that its wholly owned subsidiary, Solta Medical Corporation, has publicly filed for a proposed initial public offering (IPO). Solta, a provider of dermatology-focused lasers, has applied to list its common shares on the Nasdaq Global Select M
- Ocular Therapeutix Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-topline-results-for-phase-2-clinical-trial-of-otx-ded-for-the-short-term-treatment-of-dry-eye-disease/2480496/Ocular Therapeutix announced positive topline results from its phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The phase 2 clinical trial is a US-based, randomized, double-masked, vehicle-controlled, m
- Hoya Vision Care and Haag-Streit Partner to Combat Myopiahttps://modernod.com/news/hoya-vision-care-and-haag-streit-partner-to-combat-myopia/2480322/Hoya Vision Care announced a strategic partnership with Haag-Streit to help address the global rise of myopia in children. The global sales and marketing agreement creates a preferred partnership between Hoya Vision Care and Haag-Streit to provide eye care professionals (ECPs) with Lenstar M